Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | DRD3 | P35462 | 4/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.34 |
| ▸ | HRH2 | P25021 | 2/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12271477 | 1.00 | CYP2C9 (0.52) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL15468904 | 1.00 | CYP2C9 (0.52) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL15854040 | 1.00 | CYP2C9 (0.52) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL16743566 | 1.00 | CYP2C9 (0.52) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL15854041 | 0.90 | MAPK1 (0.43) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL7939654 | 0.90 | MAPK1 (0.43) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL16743568 | 0.90 | MAPK1 (0.43) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL15469017 | 0.90 | MAPK1 (0.43) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL20756547 | 0.86 | LMNA (0.42) | CYP2C9LMNA | |
| SCHEMBL20858048 | 0.81 | OPRM1 (0.34) | CYP2C9LMNAOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397661-A1 | COMPOUND FOR DEGRADATION OF BCL-2 FAMILY PROTEINS AND MEDICAL APPLICATION THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-07-10 | — | — | EP | disclosed |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-3967695-B1 | 1-(7-(QUINAZOLIN-4-YL)-2,7-DIAZASPIRO[3.5]NONAN-2-YL)PROP-2-EN-1-ONE DERIVATIVES AS KRAS INHIBITORS FOR THE TREATMENT OF CANCER | BETTA PHARMACEUTICALS CO LTD (CN) | 2024-01-17 | — | — | EP | disclosed |
| WO-2024003535-A2 | COMPOUNDS | UNIVERSITY OF DUNDEE (GB) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023239892-A1 | COMPOUNDS FOR MODULATION OF CD68 AND USES THEREOF | ARKUDA THERAPEUTICS (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2023-11-07 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20120010406-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100105659-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPPHARMA INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-7291612-B2 | Immunomodulatory compounds | ACTIVE BIOTECH A.B. (SE) | 2007-11-06 | — | — | US | disclosed |
| US-20070161578-A1 | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist | SCHERING CORPORATION | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | CYP2C9 3488/4885LMNA 1800/4885SLC6A2 2851/4885 |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | CYP2C9 4360/4885LMNA 4281/4885SLC6A2 4515/4885 |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | P2RX4, P2RX5, P2RX3 | CYP2C9 932/4885LMNA 2734/4885SLC6A2 864/4885 |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | CYP2C9 4870/4885LMNA 3909/4885SLC6A2 187/4885 |
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | DCX, NGF, BDNF | CYP2C9 4883/4885LMNA 2587/4885SLC6A2 956/4885 |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CYP2C9 2743/4885LMNA 3892/4885SLC6A2 4861/4885 |
| US-20100105659-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | CYP2C9 3255/4885LMNA 4132/4885SLC6A2 1836/4885 |
| US-20120010406-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CYP2C9 2743/4885LMNA 3892/4885SLC6A2 4861/4885 |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | IRAK4, FLT3, IRAK2 | CYP2C9 1974/4885LMNA 2982/4885SLC6A2 4865/4885 |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ENTPD1, ADORA2A | CYP2C9 2171/4885LMNA 1207/4885SLC6A2 64/4885 |
| US-20070161578-A1 | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist | NR1H4, NR1H3, NR1H2 | CYP2C9 3485/4885LMNA 1600/4885SLC6A2 1003/4885 |
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | HTR5A, CRH, CYP17A1 | CYP2C9 164/4885LMNA 1414/4885SLC6A2 99/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | CYP2C9 3625/4885LMNA 2894/4885SLC6A2 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.